WHAT IS CLAIMED IS:

1. A synthetic pediatric formula comprising a human milk oligosaccharide and from about 0.025 mg/mL to about 0.130 mg/mL of a long chain polyunsaturated fatty acid.

2. The synthetic pediatric formula of claim 1, wherein the human milk oligosaccharide is selected from the group consisting of 6'-sialyllactose, 2'- fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

3. The synthetic pediatric formula of claim 2, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

4. The synthetic pediatric formula of claim 2, wherein the human milk oligosaccharide is 6'-sialyllactose.

5. The synthetic pediatric formula of claim 4, wherein the 6'-sialyllactose is present in a concentration of from about 0.001 mg/mL to about 20 mg/mL.

6. The synthetic pediatric formula of claim 5, wherein the 6'-sialyllactose is present in a concentration of from about 0.001 mg/mL to less than 0.25 mg/mL.

7. The synthetic pediatric formula of claim 5, wherein the 6'-sialyllactose is present in a concentration of from greater than 0.4 mg/mL to 20 mg/mL.

8. A synthetic pediatric formula comprising a human milk oligosaccharide and from about 0.001 μg/mL to about 10 μg/mL of a carotenoid.

9. The synthetic pediatric formula of claim 8, wherein the carotenoid is present in a concentration of from about 0.001 μg/mL to about 5 μg/mL.

10. The synthetic pediatric formula of claim 8, wherein the human milk oligosaccharide is selected from the group consisting of 6'-sialyllactose, 2'- fucosyllactose, and combinations thereof and the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof.

11. A method of reducing inflammation in an infant, toddler, or child, the method comprising administering to the infant, child or toddler a composition comprising a human milk oligosaccharide and from about 0.025 mg/mL to about 0.130 mg/mL of a long chain polyunsaturated fatty acid.

12. The method of claim 11, wherein the human milk oligosaccharide is selected from the group consisting of 6'-sialyllactose, 2'- fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

13. The method of claim 11, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

14. The method of claim 11, wherein the human milk oligosaccharide is 6'-sialyllactose.

15. The method of claim 14, wherein the 6'-sialyllactose is present in a concentration of from about 0.001 mg/mL to about 20 mg/mL.

What is claimed is:

1. A synthetic pediatric formula comprising a human milk oligosaccharide and 0.025 mg/mL to 0.130 mg/mL of a long chain polyunsaturated fatty acid.

2. The synthetic pediatric formula of claim 1, wherein the human milk oligosaccharide is selected from the group consisting of 6' -sialyllactose, 2' - fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

3. The synthetic pediatric formula of claim 2, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

4. The synthetic pediatric formula of claim 2, wherein the human milk oligosaccharide is 6' - sialyllactose.

5. The synthetic pediatric formula of claim 4, wherein the 6'-sialyllactose is present in a concentration of 0.001 mg/mL to 20 mg/mL.

6. The synthetic pediatric formula of claim 5, wherein the 6'-sialyllactose is present in a concentration of 0.001 mg/mL to less than 0.25 mg/mL.

7. The synthetic pediatric formula of claim 5, wherein the 6'-sialyllactose is present in a concentration of from greater than 0.4 mg/mL to 20 mg/mL.

8. A synthetic pediatric formula comprising a human milk oligosaccharide and 0.001 μg/mL to 10 μg/mL of a carotenoid.

9. The synthetic pediatric formula of claim 8, wherein the carotenoid is present in a concentration of 0.001 μg/mL to 5 μg/mL.

10. The synthetic pediatric formula of claim 8, wherein the human milk oligosaccharide is selected from the group consisting of 6' -sialyllactose, 2' - fucosyllactose, and combinations

thereof and the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof.

11. A composition comprising (a) a human milk oligosaccharide and (b) at least one of (i) 0.025 mg/mL to 0.130 mg/mL of a long chain polyunsaturated fatty acid, and (ii) 0.001 μg/mL to 10 μg/mL of a carotenoid, for use in the treatment and/or prevention of an inflammatory condition or disease in an infant, toddler, or child by reducing said inflammation.

12. The composition of claim 11, wherein the human milk oligosaccharide is selected from the group consisting of 6' -sialyllactose, 2'- fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

13. The composition of claim 11, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

14. The composition of claim 11, wherein the human milk oligosaccharide is 6'-sialyllactose.

15. The composition of claim 14, wherein the 6'-sialyllactose is present in a concentration of 0.001 mg/mL to 20 mg/mL.

16. The composition of claim 11, wherein the inflammatory disease or condition is virus-induced.